Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Dec 11, 2024 6:49pm

71 Views

Post# 36357847

RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

That's a bad thing Noteable? We're in a holding pattern. Buy, hold and buy the dips if you can. Talking about in lieu of news doesn't help or hurt. We'll get to $30 soon enough and those who FUDed will be on here making excuses again.

<< Previous

Bullboard Posts

Next >>

Corus reports Q1 profit drop in the face of falling revenue